FDA's Oncologic Drugs Advisory Committee recommended FDA approve Novartis AG's tisagenlecleucel (CTL019) July 12, all but guaranteeing the drug will be the first chimeric antigen receptor T cell (CAR-T) therapy to reach the market. The focus now for Novartis and investors will be on how the company will turn its CAR-T platform into a commercial success story.
Novartis' CAR-T Poised For The Market After Unanimous FDA Adcomm Review
FDA's Oncologic Drugs Advisory Committee recommends 10-0 the agency approve Novartis' tisagenlecleucel (CTL019) for pediatric leukemia in a panel review that was hailed by some in the industry as historic.
